Valneva Faces Legal Scrutiny Following Vaccine Data Setback

Valneva shares crash 39.5% after mixed Lyme disease vaccine trial results, prompting U.S. law firms to investigate potential securities fraud. Pfizer maintains regulatory plans.

A steep decline in Valneva's share price, triggered by mixed clinical trial results for its Lyme disease vaccine candidate, has now attracted the attention of U.S. law firms. Investigations into potential securities fraud have been initiated, with attorneys actively recruiting affected investors to join possible legal action. What began as a clinical and statistical setback has escalated into a significant crisis of investor confidence.

Legal Investigations Commence

Specialized U.S. law firms have moved swiftly in response to the equity's dramatic fall. Pomerantz LLP announced on Tuesday that it is commencing an official investigation into the biotech firm and its officers. The core allegation is that Valneva may have failed to properly communicate the risks and the statistical validity of the trial data to the market ahead of the release. The firm is calling on investors who have suffered substantial losses to come forward.

The turmoil originates from Phase 3 data for the vaccine candidate PF-07307405, released on Monday. While Valneva and its partner Pfizer demonstrated an efficacy rate of approximately 73 percent, the study failed to meet a key pre-defined statistical endpoint in one analysis. The market's reaction to this ambiguity was severe. Shares plummeted 39.50 percent over the week, closing yesterday at just €2.88. A Relative Strength Index (RSI) reading of 18.8 indicates the stock is now in extremely oversold territory.

Pfizer Maintains Regulatory Path

Despite the emerging legal threat, the development partners are sticking to their strategic timeline. Pfizer has emphasized that the overall data continues to support the clinical benefit of the vaccine and is proceeding with plans for global regulatory submissions. With no currently approved human vaccine for Lyme disease available worldwide, the companies assess the medical need as remaining high.

From a financial perspective, Valneva reports a stable near-term position with cash reserves of nearly €110 million, projected to last until the end of 2025.

The short-term trajectory for the stock now hinges critically on how regulatory authorities interpret the companies' data. However, until a concrete decision on the marketing applications is reached, the looming specter of litigation presents a substantial overhang, likely to hinder any sustained recovery in the share price.